
Medivector Inc., Boston, Massachusetts, was awarded a $30,000,000 contract, for Phase 2 clinical trials for efficacy testing to include any associated data as may be useful for the Investigational New Drug filing of the product Favipiravir which is directed at development of a medical countermeasure against a validated biological warfare agent (Ebola).
Work will be performed in Boston, MA and in Africa, with an estimated completion date of Nov. 14, 2015. Fiscal 2015 research, development, testing and evaluation funds in the amount of $7,900,000 are being obligated at the time of the award. Army Contracting Command, Natick, Massachusetts, is the contracting activity (W911QY-15-C-0011).



